Portage Learning| BIOL351/BIOD351 Pharmacology Module
4 Exams All Versions; Latest Questions With Verified Answers
Institution: Portage Learning
Course Code: BIOL351/BIOD351
Course Title: Pharmacology
Exam: Module 4 Exams
Topic: Endocrinology
Edition: Updated Version
Student Name: _______________________________
Student Id: _________________________________
Instructor: _________________________________
Instructions:
• Answer All Questions.
• Choose The Correct Answer
QUESTIONS TYPE:
➢ Multiple Choice:
➢ True Or False:
➢ Explain/Describe/ Identification
➢ Fill In The Blank
➢ Short Answer
All The Best!!
, Module 4. Endocrinology
Refer To The Physiological Pathways Below Demonstrating Normal Insulin Action
Versus Metabolic Dysfunction. To Answer Questions; 1, 2 And 3
Scenario:
A 54-Year-Old Male With A History Of Obesity Presents With A Hemoglobin A1c Of
8.5%. He Is Diagnosed With Type II Diabetes, Which Is Illustrated In The Bottom Panel
Of The Diagram. The Primary Pathology Involves A Defect In The Insulin Signaling
Pathway, Leading To A Failure Of GLUT4 Transporter Translocation To The Cell
Surface.
Question 1.
Mechanism Identification: Which Oral Antidiabetic Drug Class Directly Addresses The
Pathophysiology Shown In The Type II Diabetes Panel By Activating AMPK, Thereby
Reducing Hepatic Glucose Output And Increasing Peripheral Insulin Sensitivity Without
Stimulating Insulin Secretion?
A. Sulfonylureas
B. Biguanides (Metformin)
C. Thiazolidinediones
D. Alpha-Glucosidase Inhibitors
,ANS. B.
Explanation: Metformin Is A Biguanide That Activates AMPK And Primarily Decreases
Hepatic Glucose Production While Increasing Peripheral Insulin Sensitivity. It Does Not
Directly Stimulate Pancreatic Insulin Secretion.
Question 2.
Clinical Application: If This Patient Were Instead A Type I Diabetic (As Shown In The
Middle Panel), Explain Why Oral Medications Like Sulfonylureas (Which Stimulate
Pancreatic Beta Cells) Would Be Completely Ineffective.
ANS. Type I Diabetes Involves Autoimmune Destruction Of Pancreatic Beta Cells. As
Seen In The Middle Panel, There Is No Endogenous Insulin Production. Sulfonylureas
Require Functional Beta Cells To Exert Their Mechanism; Therefore, They Cannot
Function In A Type I Diabetic.
Explanation: Sulfonylureas Work By Stimulating Functioning Pancreatic Beta Cells To
Release Insulin. In Type I Diabetes, The Beta Cells Have Been Destroyed, So There Is
Little Or No Endogenous Insulin Available For Sulfonylureas To Stimulate.
Question 3.
High-Yield Side Effect: What Is The Most Severe, Black-Box Warning Adverse Effect
Associated With Metformin (Biguanide) Therapy, Particularly In Patients With
Underlying Renal Impairment?
A. Severe Hypoglycemia
B. Lactic Acidosis
C. Agranulocytosis
D. Hyperthyroidism
ANS. B.
Explanation: Metformin Can Cause Accumulation Of Lactate, And The Risk Of
Potentially Life-Threatening Lactic Acidosis Increases When Renal Impairment Prevents
Adequate Clearance Of The Drug.
, Refer To The Homeostatic Feedback Loop Regulating Blood Glucose Levels Below. To
Answer Questions; 4, 5 And 6.
Scenario:
A Diabetic Patient Accidentally Administers Too Much Short-Acting Insulin Prior To A
Meal, Plunging Them Into Severe Hypoglycemia (Represented By The Lower Pathway).
The Patient Becomes Unconscious And Is Unable To Swallow Oral Carbohydrates.
Question 4.
Emergency Therapeutics: Based On The Physiological Responses Shown In The Lower
Feedback Loop, What Emergency Hormone Injection Can Be Administered To Rapidly
Reverse This Patient's Hypoglycemia In An Outpatient Setting?
A. Insulin
B. Glucagon
C. Thyroxine
D. Cortisol
ANS. B.
Explanation: Glucagon Is The Counter-Regulatory Hormone To Insulin And Can Be
Administered As An Emergency Rescue Medication For Severe Hypoglycemia,
Especially When The Patient Is Unconscious And Unable To Take Oral Carbohydrates.
Question 5.
4 Exams All Versions; Latest Questions With Verified Answers
Institution: Portage Learning
Course Code: BIOL351/BIOD351
Course Title: Pharmacology
Exam: Module 4 Exams
Topic: Endocrinology
Edition: Updated Version
Student Name: _______________________________
Student Id: _________________________________
Instructor: _________________________________
Instructions:
• Answer All Questions.
• Choose The Correct Answer
QUESTIONS TYPE:
➢ Multiple Choice:
➢ True Or False:
➢ Explain/Describe/ Identification
➢ Fill In The Blank
➢ Short Answer
All The Best!!
, Module 4. Endocrinology
Refer To The Physiological Pathways Below Demonstrating Normal Insulin Action
Versus Metabolic Dysfunction. To Answer Questions; 1, 2 And 3
Scenario:
A 54-Year-Old Male With A History Of Obesity Presents With A Hemoglobin A1c Of
8.5%. He Is Diagnosed With Type II Diabetes, Which Is Illustrated In The Bottom Panel
Of The Diagram. The Primary Pathology Involves A Defect In The Insulin Signaling
Pathway, Leading To A Failure Of GLUT4 Transporter Translocation To The Cell
Surface.
Question 1.
Mechanism Identification: Which Oral Antidiabetic Drug Class Directly Addresses The
Pathophysiology Shown In The Type II Diabetes Panel By Activating AMPK, Thereby
Reducing Hepatic Glucose Output And Increasing Peripheral Insulin Sensitivity Without
Stimulating Insulin Secretion?
A. Sulfonylureas
B. Biguanides (Metformin)
C. Thiazolidinediones
D. Alpha-Glucosidase Inhibitors
,ANS. B.
Explanation: Metformin Is A Biguanide That Activates AMPK And Primarily Decreases
Hepatic Glucose Production While Increasing Peripheral Insulin Sensitivity. It Does Not
Directly Stimulate Pancreatic Insulin Secretion.
Question 2.
Clinical Application: If This Patient Were Instead A Type I Diabetic (As Shown In The
Middle Panel), Explain Why Oral Medications Like Sulfonylureas (Which Stimulate
Pancreatic Beta Cells) Would Be Completely Ineffective.
ANS. Type I Diabetes Involves Autoimmune Destruction Of Pancreatic Beta Cells. As
Seen In The Middle Panel, There Is No Endogenous Insulin Production. Sulfonylureas
Require Functional Beta Cells To Exert Their Mechanism; Therefore, They Cannot
Function In A Type I Diabetic.
Explanation: Sulfonylureas Work By Stimulating Functioning Pancreatic Beta Cells To
Release Insulin. In Type I Diabetes, The Beta Cells Have Been Destroyed, So There Is
Little Or No Endogenous Insulin Available For Sulfonylureas To Stimulate.
Question 3.
High-Yield Side Effect: What Is The Most Severe, Black-Box Warning Adverse Effect
Associated With Metformin (Biguanide) Therapy, Particularly In Patients With
Underlying Renal Impairment?
A. Severe Hypoglycemia
B. Lactic Acidosis
C. Agranulocytosis
D. Hyperthyroidism
ANS. B.
Explanation: Metformin Can Cause Accumulation Of Lactate, And The Risk Of
Potentially Life-Threatening Lactic Acidosis Increases When Renal Impairment Prevents
Adequate Clearance Of The Drug.
, Refer To The Homeostatic Feedback Loop Regulating Blood Glucose Levels Below. To
Answer Questions; 4, 5 And 6.
Scenario:
A Diabetic Patient Accidentally Administers Too Much Short-Acting Insulin Prior To A
Meal, Plunging Them Into Severe Hypoglycemia (Represented By The Lower Pathway).
The Patient Becomes Unconscious And Is Unable To Swallow Oral Carbohydrates.
Question 4.
Emergency Therapeutics: Based On The Physiological Responses Shown In The Lower
Feedback Loop, What Emergency Hormone Injection Can Be Administered To Rapidly
Reverse This Patient's Hypoglycemia In An Outpatient Setting?
A. Insulin
B. Glucagon
C. Thyroxine
D. Cortisol
ANS. B.
Explanation: Glucagon Is The Counter-Regulatory Hormone To Insulin And Can Be
Administered As An Emergency Rescue Medication For Severe Hypoglycemia,
Especially When The Patient Is Unconscious And Unable To Take Oral Carbohydrates.
Question 5.
